Characterization of CD8⁺ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions

References

• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–11. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371(23):2189–2199. doi:10.1056/NEJMoa1406498.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124–128. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207–211. doi:10.1126/science.aad0095.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013;19(6):747–752. doi:10.1038/nm.3161.
   PubMed Web of Science ®Google Scholar
• Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res 2014;20(13):3401–3410. doi:10.1158/1078-0432.CCR-14-0433.
   PubMed Web of Science ®Google Scholar
• Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015;350(6266):1387–1390. doi:10.1126/science.aad1253.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, et al. T-Cell transfer therapy targeting mutant KRAS in Cancer. N Engl J Med 2016;375(23):2255–2262. doi:10.1056/NEJMoa1609279.
   PubMed Web of Science ®Google Scholar
• Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y-C, Zheng Z, Pasetto A, Langhan M, Shelton T, Prickett T, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;6. doi:10.1038/s41591-018-0040-8
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov 2019;9(8):1022–1035. doi:10.1158/2159-8290.CD-18-1494.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014;515(7528):572–576. doi:10.1038/nature14001.
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515(7528):577–581. doi:10.1038/nature13988.
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Braunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016;7(1):13404. doi:10.1038/ncomms13404.
   PubMed Web of Science ®Google Scholar
• Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 2016;7(5):5110–5117. doi:10.18632/oncotarget.6960.
   PubMedGoogle Scholar
• Kochin V, Kanaseki T, Tokita S, Miyamoto S, Shionoya Y, Kikuchi Y, Morooka D, Hirohashi Y, Tsukahara T, Watanabe K, et al. HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. Oncoimmunology 2017;6(4):e1293214. doi:10.1080/2162402X.2017.1293214.
   PubMed Web of Science ®Google Scholar
• Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, et al. Combined analysis of antigen presentation and T-cell Recognition reveals restricted immune responses in melanoma. Cancer Discov 2018;8(11):1366–1375. doi:10.1158/2159-8290.CD-17-1418.
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Nik H, Michaux J, Corwin WL, Keller GL, Shcheglova T, Pak H, et al. Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection. JCI Insight. 2019;4(14):129152.doi:10.1172/jci.insight.129152.
   Web of Science ®Google Scholar
• Loffler MW, Mohr C, Bichmann L, Freudenmann LK, Walzer M, Schroeder CM, Trautwein N, Hilke FJ, Zinser RS, Muhlenbruch L, et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med 2019;11(1):28. doi:10.1186/s13073-019-0636-8.
   PubMed Web of Science ®Google Scholar
• Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, et al. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. Journal for Immunotherapy of Cancer 2019;7(1):309. doi:10.1186/s40425-019-0769-8.
   PubMed Web of Science ®Google Scholar
• Freudenmann LK, Marcu A, Stevanovic S. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. Immunology. 2018;154(3):331–345. doi:10.1111/imm.12936.
   PubMed Web of Science ®Google Scholar
• Kanaseki T, Tokita S, Torigoe T. Proteogenomic discovery of cancer antigens: neoantigens and beyond. Pathol Int. 2019;9. doi:10.1111/pin.12841.
   PubMed Web of Science ®Google Scholar
• Haen SP, Loffler MW, Rammensee HG, Brossart P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol. 2020;10. doi:10.1038/s41571-020-0387-x.
   PubMed Web of Science ®Google Scholar
• Abelin JG, Keskin DB, Sarkizova S, Hartigan CR, Zhang W, Sidney J, Stevens J, Lane W, Zhang GL, Eisenhaure TM, et al. Mass spectrometry profiling of HLA-Associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 2017;46(2):315–326. doi:10.1016/j.immuni.2017.02.007.
   PubMed Web of Science ®Google Scholar
• Hongo A, Kanaseki T, Tokita S, Kochin V, Miyamoto S, Hashino Y, Codd A, Kawai N, Nakatsugawa M, Hirohashi Y, et al. Upstream position of proline defines Peptide–HLA Class I Repertoire Formation and CD8+T Cell Responses. J Immunol. 2019;10. doi:10.4049/jimmunol.1900029
   PubMed Web of Science ®Google Scholar
• Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020;48:W449–W54. doi:10.1093/nar/gkaa379.
   PubMed Web of Science ®Google Scholar
• Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014;2(6):522–529. doi:10.1158/2326-6066.CIR-13-0227.
   PubMed Web of Science ®Google Scholar
• Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP, Blanchard T, McMahon D, Sidney J, Sette A, et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014;211(11):2231–2248. doi:10.1084/jem.20141308.
   PubMed Web of Science ®Google Scholar
• Capietto AH, Jhunjhunwala S, Pollock SB, Lupardus P, Wong J, Hansch L, Cevallos J, Chestnut Y, Fernandez A, Lounsbury N, et al. Mutation position is an important determinant for predicting cancer neoantigens. J Exp Med. 2020;(4):217. doi:10.1084/jem.20190179.
   Web of Science ®Google Scholar
• Gattoni-Celli S, Kirsch K, Timpane R, Isselbacher KJ. Beta 2-microglobulin gene is mutated in a human colon cancer cell line (HCT) deficient in the expression of HLA class I antigens on the cell surface. Cancer Res. 1992;52:1201–1204.
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. doi:10.1016/j.cell.2014.12.033.
   PubMed Web of Science ®Google Scholar
• Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H, Nakatsugawa M, Nishizawa S, Tamura Y, Tsuruma T, et al. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol 2011;178(4):1805–1813. doi:10.1016/j.ajpath.2011.01.004.
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. 2015;14(3):658–673. doi:10.1074/mcp.M114.042812.
   PubMed Web of Science ®Google Scholar
• Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Boschen ML, Lund-Johansen F, Olweus J, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;6291. doi:10.1126/science.aaf2288
   PubMed Web of Science ®Google Scholar
• Wolfl M, Greenberg PD. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc. 2014;9(4):950–966. doi:10.1038/nprot.2014.064.
   PubMed Web of Science ®Google Scholar
• Harndahl M, Rasmussen M, Roder G, Dalgaard Pedersen I, Sorensen M, Nielsen M, Buus S. Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 2012;42(6):1405–1416. doi:10.1002/eji.201141774.
   PubMed Web of Science ®Google Scholar
• Luksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 2017;551(7681):517–520. doi:10.1038/nature24473.
   PubMed Web of Science ®Google Scholar
• Rech AJ, Balli D, Mantero A, Ishwaran H, Nathanson KL, Stanger BZ, Vonderheide RH. Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunol Res. 2018;3. 10.1158/2326-6066.CIR-17-0559
   PubMed Web of Science ®Google Scholar
• Ghorani E, Rosenthal R, McGranahan N, Reading JL, Lynch M, Peggs KS,  Swanton C, Quezada SA. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018;29:271–279. doi:10.1093/annonc/mdx687.
   PubMed Web of Science ®Google Scholar
• Riley TP, Keller GLJ, Smith AR, Davancaze LM, Arbuiso AG, Devlin JR, Baker BM. Structure based prediction of neoantigen immunogenicity. Front Immunol. 2019; pp.10. doi:10.3389/fimmu.2019.02047
   PubMed Web of Science ®Google Scholar
• Lamiable A, Thevenet P, Rey J, Vavrusa M, Derreumaux P, Tuffery P. PEP-FOLD3: fasterde novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Res. 2016;44(W1):W449–54. doi:10.1093/nar/gkw329.
   PubMed Web of Science ®Google Scholar
• Chowell D, Krishna S, Becker PD, Cocita C, Shu J, Tan X, Greenberg PD, Klavinskis LS, Blattman JN, Anderson KS. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8 T cell epitopes. Proc Natl Acad Sci U S A 2015;112(14):E1754–62. doi:10.1073/pnas.1500973112.
   PubMed Web of Science ®Google Scholar
• Teku GN, Vihinen M. Pan-cancer analysis of neoepitopes. Sci Rep. 2018;8(1):12735. doi:10.1038/s41598-018-30724-y.
   PubMed Web of Science ®Google Scholar
• Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. 2012;12(9):669–677. doi:10.1038/nri3279.
   PubMed Web of Science ®Google Scholar
• Zhang SQ, Ma KY, Schonnesen AA, Zhang M, He C, Sun E, Williams CM, Jia W, Jiang N. High-throughput determination of the antigen specificities of T cell receptors in single cells. Nat Biotechnol. 2018;12. 10.1038/nbt.4282
   Web of Science ®Google Scholar
• Bentzen AK, Such L, Jensen KK, Marquard AM, Jessen LE, Miller NJ, Church CD, Lyngaa R, Koelle DM, Becker JC, et al. T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes. Nat Biotechnol. 2018. doi:10.1038/nbt.4303.
   PubMed Web of Science ®Google Scholar
• Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Bakir MA, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017;18(8):1009–1021. doi:10.1016/S1470-2045(17)30516-8.
   PubMed Web of Science ®Google Scholar
• Mandal R, Samstein RM, Lee KW, Havel JJ, Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 2019;364(6439):485–491. doi:10.1126/science.aau0447.
   PubMed Web of Science ®Google Scholar
• Leng Q, Tarbe M, Long Q, Wang F. Pre-existing heterologous T-cell immunity and neoantigen immunogenicity. Clin Transl Immunol. 2020;9:e1111. doi:10.1002/cti2.1111.
   Web of Science ®Google Scholar
• Fluckiger A, Daillere R, Sassi M, Sixt BS, Liu P, Loos F, Richard C, Rabu C, Alou MT, Goubet AG, et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science 2020;369(6506):936–942. doi:10.1126/science.aax0701.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 2017;551(7681):512–516. doi:10.1038/nature24462.
   PubMed Web of Science ®Google Scholar
• Wells DK, van Buuren MM, Dang KK, Hubbard-Lucey VM, Sheehan KCF, Campbell KM, Lamb A, Ward JP, Sidney J, Blazquez AB, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020);3. 10.1016/j.cell.2020.09.015
   Web of Science ®Google Scholar
• Scholtalbers J, Boegel S, Bukur T, Byl M, Goerges S, Sorn P, Loewer M, Sahin U, Castle JC. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med 2015;7(1):118. doi:10.1186/s13073-015-0240-5.
   PubMed Web of Science ®Google Scholar
• Nakatsugawa M, Hirohashi Y, Torigoe T, Inoda S, Kiriyama K, Tamura Y, Sato E, Takahashi H, Sato N. Comparison of speedy PCR-ssp method and serological typing of HLA-A24 for Japanese cancer patients. J Immunoassay Immunochem 2011;32(2):93–102. doi:10.1080/15321819.2010.543219.
   PubMed Web of Science ®Google Scholar
• Kowalewski DJ, Stevanovic S. Biochemical large-scale identification of MHC class I ligands. Methods Mol Biol. 2013;960:145–157.
   PubMedGoogle Scholar
• Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 2017;45(D1):D777–D83. doi:10.1093/nar/gkw1121.
   PubMed Web of Science ®Google Scholar
• Chang CX, Tan AT, Or MY, Toh KY, Lim PY, Chia AS, Froesig TM, Nadua KD, Oh HLJ, Leong HN, et al. Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. Eur J Immunol 2013;43(4):1109–1120. doi:10.1002/eji.201243088.
   PubMed Web of Science ®Google Scholar
• Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, Ovaa H. Generation of peptide–MHC class I complexes through UV-mediated ligand exchange. Nat Protoc. 2006;1(3):1120–1132. doi:10.1038/nprot.2006.121.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Kochin V, Kanaseki T, Hongo A, Tokita S, Kikuchi Y, Takaya A, Hirohashi Y, Tsukahara T, Terui T, et al. The antigen ASB4 on cancer stem cells serves as a target for CTL immunotherapy of colorectal cancer. Cancer Immunol Res. 2018;6(3):358–369. doi:10.1158/2326-6066.CIR-17-0518.
   PubMed Web of Science ®Google Scholar
• London N, Raveh B, Cohen E, Fathi G, Rosetta FlexPepDock S-FO. web server–high resolution modeling of peptide-protein interactions. Nucleic Acids Res. 2011;39(suppl_2):W249–53. doi:10.1093/nar/gkr431.
   PubMed Web of Science ®Google Scholar
• Osorio D, Rondon-Villarreal P, Torres R. Peptides: A Package for Data Mining of Antimicrobial Peptides. The R Journal 2015; 7
   Google Scholar
• Dayhoff MO, Schwartz RM, Orcutt BC. Chapter 22: A model of evolutionary change in proteins. In Atlas of protein sequence and structure. 1978; Vol. 5. 345–352
   Google Scholar